131 related articles for article (PubMed ID: 37634663)
1. Evaluation of the therapeutic efficacy of
Csikos C; Képes Z; Fekete A; Vágner A; Nagy G; Gyuricza B; Arató V; Kárpáti L; Mándity I; Bruchertseifer F; Halmos G; Szikra D; Trencsényi G
Int J Pharm; 2023 Sep; 644():123344. PubMed ID: 37634663
[TBL] [Abstract][Full Text] [Related]
2. In Vivo evaluation of newly synthesized
Kálmán-Szabó I; Képes Z; Fekete A; Vágner A; Nagy G; Szücs D; Gyuricza B; Arató V; Varga J; Kárpáti L; Garai I; Mándity I; Bruchertseifer F; Elek J; Szikra D; Trencsényi G
J Pharm Biomed Anal; 2023 May; 229():115374. PubMed ID: 37001274
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific
Nagy G; Dénes N; Kis A; Szabó JP; Berényi E; Garai I; Bai P; Hajdu I; Szikra D; Trencsényi G
Eur J Pharm Sci; 2017 Aug; 106():336-344. PubMed ID: 28625749
[TBL] [Abstract][Full Text] [Related]
4. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
[TBL] [Abstract][Full Text] [Related]
5. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
6. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
[TBL] [Abstract][Full Text] [Related]
7. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.
Bapst JP; Froidevaux S; Calame M; Tanner H; Eberle AN
J Recept Signal Transduct Res; 2007; 27(5-6):383-409. PubMed ID: 18097939
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of
Xu J; Gallazzi F; Fisher DR; Gonzalez R; Miao Y
Cancer Biother Radiopharm; 2022 Feb; 37(1):47-55. PubMed ID: 34762521
[No Abstract] [Full Text] [Related]
9. Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of
Szücs D; Szabó JP; Arató V; Gyuricza B; Szikra D; Tóth I; Képes Z; Trencsényi G; Fekete A
Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765089
[TBL] [Abstract][Full Text] [Related]
10. Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors.
Cantorias MV; Figueroa SD; Quinn TP; Lever JR; Hoffman TJ; Watkinson LD; Carmack TL; Cutler CS
Nucl Med Biol; 2009 Jul; 36(5):505-13. PubMed ID: 19520291
[TBL] [Abstract][Full Text] [Related]
11. Novel [
Qiao Z; Xu J; Gonzalez R; Miao Y
Mol Pharm; 2020 Sep; 17(9):3581-3588. PubMed ID: 32663011
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological properties of 3-arm or 4-arm DOTA constructs for conjugation to α-melanocyte-stimulating hormone analogues for melanoma imaging.
Kobayashi M; Kato T; Washiyama K; Ihara M; Mizutani A; Nishi K; Flores LG; Nishii R; Kawai K
PLoS One; 2019; 14(3):e0213397. PubMed ID: 30901323
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.
Yang J; Guo H; Gallazzi F; Berwick M; Padilla RS; Miao Y
Bioconjug Chem; 2009 Aug; 20(8):1634-42. PubMed ID: 19552406
[TBL] [Abstract][Full Text] [Related]
14. Gallium-67-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging.
Guo H; Yang J; Shenoy N; Miao Y
Bioconjug Chem; 2009 Dec; 20(12):2356-63. PubMed ID: 19919057
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Melanoma Imaging with
Zhang C; Zhang Z; Lin KS; Pan J; Dude I; Hundal-Jabal N; Colpo N; Bénard F
Theranostics; 2017; 7(4):805-813. PubMed ID: 28382155
[TBL] [Abstract][Full Text] [Related]
16. Novel
Qiao Z; Xu J; Gonzalez R; Miao Y
Mol Pharm; 2022 Jul; 19(7):2535-2541. PubMed ID: 35486894
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide.
Xu J; Yang J; Gonzalez R; Fisher DR; Miao Y
Cancer Biother Radiopharm; 2019 Nov; 34(9):597-603. PubMed ID: 31644317
[No Abstract] [Full Text] [Related]
18. Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model.
von Hacht JL; Erdmann S; Niederstadt L; Prasad S; Wagener A; Exner S; Beindorff N; Brenner W; Grötzinger C
PLoS One; 2019; 14(6):e0217883. PubMed ID: 31163066
[TBL] [Abstract][Full Text] [Related]
19. Effect of DOTA position on melanoma targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide.
Guo H; Yang J; Gallazzi F; Prossnitz ER; Sklar LA; Miao Y
Bioconjug Chem; 2009 Nov; 20(11):2162-8. PubMed ID: 19817405
[TBL] [Abstract][Full Text] [Related]
20. Novel Al
Qiao Z; Xu J; Gonzalez R; Miao Y
Bioconjug Chem; 2022 May; 33(5):982-990. PubMed ID: 35475603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
